BACKGROUND: Prospective data on factors associated with the non-AIDS-defining cancer (NADC) incidence in HIV-infected individuals are limited. METHODS: We examined the NADC incidence in 3,158 antiretroviral treatment (ART)-naïve subjects after ART initiation in AIDS Clinical Trials Group trials; extended follow-up was available for 2,122 subjects. Poisson regression was used to examine the associations between covariates and incident NADC. RESULTS: At ART initiation, subjects (median age 37 years) were 40% non-Hispanic whites, and 82% were male; 23% had CD4+ T cell count ≤ 50 cells/mm³ and 25% had CD4 >350 cells/mm³. Median follow-up was 3.8 years. Among 64 incident NADCs, the most common were 8 anal cancers, 8 basal cell carcinomas, 8 Hodgkin's disease, and 6 lung cancers. In univariate models, age, smoking and recent (time-updated) CD4 were associated with incident NADC. There was no association between initial ART drug class (protease inhibitor, nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor) and NADC. After adjusting for age, race and sex: smoking [relative risk = 2.12 (95% CI = 1.1-4.08)] and recent CD4 (≤ 50 cells/mm³: 3.58, 1.22-10.45; 51-200 cells/mm³: 2.54, 1.30-5.0; 201-350 cells/mm³: 2.37, 1.32-4.26 vs. >350 cells/mm³) were associated with NADC. CONCLUSION: Smoking and lower recent CD4 levels, but not initial ART drug class, were associated with NADC. Strategies for maintaining higher CD4 cell counts and successful smoking cessation may reduce the NADC incidence in the HIV-infected population.
BACKGROUND: Prospective data on factors associated with the non-AIDS-defining cancer (NADC) incidence in HIV-infected individuals are limited. METHODS: We examined the NADC incidence in 3,158 antiretroviral treatment (ART)-naïve subjects after ART initiation in AIDS Clinical Trials Group trials; extended follow-up was available for 2,122 subjects. Poisson regression was used to examine the associations between covariates and incident NADC. RESULTS: At ART initiation, subjects (median age 37 years) were 40% non-Hispanic whites, and 82% were male; 23% had CD4+ T cell count ≤ 50 cells/mm³ and 25% had CD4 >350 cells/mm³. Median follow-up was 3.8 years. Among 64 incident NADCs, the most common were 8 anal cancers, 8 basal cell carcinomas, 8 Hodgkin's disease, and 6 lung cancers. In univariate models, age, smoking and recent (time-updated) CD4 were associated with incident NADC. There was no association between initial ART drug class (protease inhibitor, nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor) and NADC. After adjusting for age, race and sex: smoking [relative risk = 2.12 (95% CI = 1.1-4.08)] and recent CD4 (≤ 50 cells/mm³: 3.58, 1.22-10.45; 51-200 cells/mm³: 2.54, 1.30-5.0; 201-350 cells/mm³: 2.37, 1.32-4.26 vs. >350 cells/mm³) were associated with NADC. CONCLUSION: Smoking and lower recent CD4 levels, but not initial ART drug class, were associated with NADC. Strategies for maintaining higher CD4 cell counts and successful smoking cessation may reduce the NADC incidence in the HIV-infected population.
Authors: Michael J Silverberg; Jacqueline Neuhaus; Mark Bower; Daniela Gey; Angelos Hatzakis; Keith Henry; Jose Hidalgo; Leonardo Lourtau; James D Neaton; Giuseppe Tambussi; Donald I Abrams Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: Marlene Smurzynski; Ann C Collier; Susan L Koletar; Ronald J Bosch; Kunling Wu; Barbara Bastow; Constance A Benson Journal: HIV Clin Trials Date: 2008 Jul-Aug
Authors: Pragna Patel; Debra L Hanson; Patrick S Sullivan; Richard M Novak; Anne C Moorman; Tony C Tong; Scott D Holmberg; John T Brooks Journal: Ann Intern Med Date: 2008-05-20 Impact factor: 25.391
Authors: Alexandra Nieters; Sabine Rohrmann; Nikolaus Becker; Jakob Linseisen; Thomas Ruediger; Kim Overvad; Anne Tjønneland; Anja Olsen; Naomi E Allen; Ruth C Travis; Sheila Bingham; Kay-Tee Khaw; Eva Ardanaz; M L Redondo; Mikel Basterrechea; Carmen Martinez; María-José Tormo; Stefano Rosso; Giovanna Tagliabue; Giovanna Masala; Amalia Mattiello; Rosario Tumino; Heiner Boeing; Manuela Bergmann; Rudolf Kaaks; Antonia Trichopoulou; Dimitrios Trichopoulos; Petra H Peeters; Bas Bueno-de-Mesquita; Paolo Boffetta; Paul Brennan; Pietro Ferrari; David Neasham; Eiliv Lund; Göran Berglund; Jonas Manjer; Göran Hallmans; Ingegerd Johansson; Paolo Vineis; Elio Riboli Journal: Am J Epidemiol Date: 2008-03-04 Impact factor: 4.897
Authors: Gina R Kruse; David R Bangsberg; Judith A Hahn; Jessica E Haberer; Peter W Hunt; Conrad Muzoora; John P Bennett; Jeffrey N Martin; Nancy A Rigotti Journal: AIDS Behav Date: 2014-07
Authors: Martin Hoenigl; Carlee B Moser; Nicholas Funderburg; Ronald Bosch; Amy Kantor; Yonglong Zhang; Jesper Eugen-Olsen; Malcolm Finkelman; Jochen Reiser; Alan Landay; Daniela Moisi; Michael M Lederman; Sara Gianella Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Michael J Silverberg; Chun Chao; Wendy A Leyden; Lanfang Xu; Michael A Horberg; Daniel Klein; William J Towner; Robert Dubrow; Charles P Quesenberry; Romain S Neugebauer; Donald I Abrams Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-22 Impact factor: 4.254
Authors: Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay Journal: J Infect Dis Date: 2014-05-01 Impact factor: 5.226
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177